Justin Walsh
Stock Analyst at Jones Trading
(0.95)
# 3,768
Out of 4,944 analysts
41
Total ratings
36.11%
Success rate
-11.07%
Average return
Main Sectors:
Stocks Rated by Justin Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| YMAB Y-mAbs Therapeutics | Downgrades: Hold | n/a | $8.51 | - | 2 | Aug 5, 2025 | |
| THTX Theratechnologies | Downgrades: Hold | n/a | $3.21 | - | 3 | Jul 3, 2025 | |
| LNTH Lantheus Holdings | Maintains: Buy | $122 → $109 | $53.90 | +102.23% | 9 | Jun 23, 2025 | |
| VNRX VolitionRx | Initiates: Buy | $3 | $0.63 | +378.32% | 1 | Jun 10, 2025 | |
| BLRX BioLineRx | Upgrades: Buy | $12 | $3.75 | +220.00% | 3 | May 30, 2025 | |
| CLNN Clene | Initiates: Buy | $30 | $3.70 | +710.81% | 1 | Apr 23, 2025 | |
| MNPR Monopar Therapeutics | Downgrades: Hold | n/a | $35.90 | - | 1 | Apr 2, 2025 | |
| SER Serina Therapeutics | Initiates: Buy | $11 | $5.46 | +101.47% | 1 | Mar 11, 2025 | |
| ANRO Alto Neuroscience | Initiates: Buy | $18 | $3.18 | +466.04% | 1 | Dec 16, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $42 | $15.54 | +170.27% | 1 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $22 | $3.98 | +452.76% | 2 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $3.65 | +338.36% | 1 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.44 | +719.67% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $4 | $1.06 | +277.36% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $3.46 | +478.03% | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $1.66 | +984.34% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $440 | $1.47 | +29,831.97% | 1 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $0.73 | +10,162.73% | 1 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $20 | $34.83 | -42.58% | 1 | May 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $440 → $200 | $1.65 | +12,021.21% | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $3.17 | +215.46% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $800 | $8.71 | +9,084.85% | 1 | Sep 2, 2021 |
Y-mAbs Therapeutics
Aug 5, 2025
Downgrades: Hold
Price Target: n/a
Current: $8.51
Upside: -
Theratechnologies
Jul 3, 2025
Downgrades: Hold
Price Target: n/a
Current: $3.21
Upside: -
Lantheus Holdings
Jun 23, 2025
Maintains: Buy
Price Target: $122 → $109
Current: $53.90
Upside: +102.23%
VolitionRx
Jun 10, 2025
Initiates: Buy
Price Target: $3
Current: $0.63
Upside: +378.32%
BioLineRx
May 30, 2025
Upgrades: Buy
Price Target: $12
Current: $3.75
Upside: +220.00%
Clene
Apr 23, 2025
Initiates: Buy
Price Target: $30
Current: $3.70
Upside: +710.81%
Monopar Therapeutics
Apr 2, 2025
Downgrades: Hold
Price Target: n/a
Current: $35.90
Upside: -
Serina Therapeutics
Mar 11, 2025
Initiates: Buy
Price Target: $11
Current: $5.46
Upside: +101.47%
Alto Neuroscience
Dec 16, 2024
Initiates: Buy
Price Target: $18
Current: $3.18
Upside: +466.04%
Rapport Therapeutics
Oct 18, 2024
Initiates: Buy
Price Target: $42
Current: $15.54
Upside: +170.27%
May 16, 2024
Maintains: Buy
Price Target: $15 → $22
Current: $3.98
Upside: +452.76%
May 10, 2024
Initiates: Buy
Price Target: $16
Current: $3.65
Upside: +338.36%
Apr 17, 2024
Initiates: Buy
Price Target: $20
Current: $2.44
Upside: +719.67%
Sep 7, 2023
Reinstates: Buy
Price Target: $4
Current: $1.06
Upside: +277.36%
Sep 6, 2023
Initiates: Buy
Price Target: $20
Current: $3.46
Upside: +478.03%
May 16, 2023
Initiates: Buy
Price Target: $18
Current: $1.66
Upside: +984.34%
Feb 10, 2023
Initiates: Buy
Price Target: $440
Current: $1.47
Upside: +29,831.97%
Oct 7, 2022
Initiates: Buy
Price Target: $75
Current: $0.73
Upside: +10,162.73%
May 20, 2022
Maintains: Buy
Price Target: $17 → $20
Current: $34.83
Upside: -42.58%
Apr 5, 2022
Maintains: Buy
Price Target: $440 → $200
Current: $1.65
Upside: +12,021.21%
Jan 19, 2022
Initiates: Buy
Price Target: $10
Current: $3.17
Upside: +215.46%
Sep 2, 2021
Initiates: Buy
Price Target: $800
Current: $8.71
Upside: +9,084.85%